15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Neuphoria Therapeutics Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $7.00 to $35.00 (about 5.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $21.00 sits 444% above the current $3.86. The rating mix has held broadly steady over recent months.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Neuphoria Therapeutics Inc.
As of Aug, 1 of 2 firms rate NEUP a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NEUP EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect Neuphoria Therapeutics Inc to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-4.07, growing to $-2.43 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0)., rising to $0 next year.
Top analysts covering Neuphoria Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NEUP.
#1
Joseph Pantginis
HC Wainwright & Co. · Rank #298
Hold
No targeton NEUP
Overall win rate
33%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #417
Buy
$20.00+418.1% to target
Overall win rate
33%
+ Follow
#3
Elemer Piros
Lucid Capital
Hold
$2.30-40.4% to target
Coverage
—
+ Follow
NEUP stock forecast FAQ
What is NEUP's average 12-month price target?+
The 1 analysts with a live target average $21.00 for Neuphoria Therapeutics Inc over the next 12 months, ranging from a $35.00 high to a $7.00 low.
Is NEUP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NEUP?+
The Street-high target is $35.00 (Maxim Group), and the Street-low is $7.00. The average of all 1 active targets is $21.00.
How many Wall Street analysts cover NEUP?+
2 analysts have an active rating on Neuphoria Therapeutics Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering NEUP?+
Among analysts who currently cover NEUP, Joseph Pantginis of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #298). Their current call is Hold.
What is Neuphoria Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-4.07, rising to $-2.43 the following year.
How much revenue is Neuphoria Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at —, growing to $0 next year.
Have analysts been upgrading or downgrading NEUP lately?+
As of Aug, 1 of 2 firms rate NEUP a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NEUP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
